Loading organizations...
Key people at BioRock Ventures.
BioRock Ventures is a seed-stage venture capital fund investing in therapeutics startups. It funds private life science companies developing novel, FDA-regulated therapeutic drugs. Its strategy covers all disease areas, early stages, and diverse therapeutic modalities, aiming to foster significant medical advancements.
Founded by Mary Wheeler, PhD, MBA, Managing Director, BioRock Ventures leverages two decades of biopharma operating experience. Her background includes founding a therapeutics startup and leading M&A at major pharmaceutical firms. Established around 2019, her deep industry insight and successful venture backing shaped the fund’s specialized focus.
BioRock Ventures supports nascent therapeutics companies needing early capital and strategic guidance. Its mission is to empower enterprises creating breakthrough medicines for critical health challenges. By fostering innovative, FDA-regulated therapies, the firm aims to advance patient treatment and shape future medical progress.
Key people at BioRock Ventures.
BioRock Ventures has 3 tracked investments across 2 companies. The latest tracked deal is $27.0M Series A in Primmune Therapeutics in October 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2020 | Primmune Therapeutics | $27.0M Series A | CAM Capital, Amir Nashat | Domain Associates, Polaris Partners, BioBrit, Mcdermott, Andrew Rubinstein, Samsara BioCapital |
| Mar 2, 2020 | Primmune Therapeutics | $7.0M Seed | — | Charlie Mcdermott, BioBrit, Scott Morenstein |
| Nov 1, 2019 | AN2 Therapeutics | $12.0M Series A | Mountain Group Partners | Adjuvant Capital, Brii Biosciences |
